Maia Pharms Inc Company Profile

What is the competitive landscape for MAIA PHARMS INC

MAIA PHARMS INC has ten approved drugs.

There are nine US patents protecting MAIA PHARMS INC drugs.

There are four patent family members on MAIA PHARMS INC drugs in three countries and seventy-seven supplementary protection certificates in nine countries.

Summary for Maia Pharms Inc

International Patents:	4
US Patents:	9
Tradenames:	7
Ingredients:	7
NDAs:	10

Drugs and US Patents for Maia Pharms Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Maia Pharms Inc	ANGIOMAX RTU	bivalirudin	SOLUTION;INTRAVENOUS	211215-001	Jul 25, 2019		RX	Yes	Yes	11,992,514		Y
Maia Pharms Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	POWDER;INTRAVENOUS	208749-002	Dec 21, 2018	AP	RX	No	No
Maia Pharms Inc	DAPTOMYCIN	daptomycin	POWDER;INTRAVENOUS	217630-002	Nov 21, 2024		RX	Yes	Yes
Maia Pharms Inc	ANGIOMAX RTU	bivalirudin	SOLUTION;INTRAVENOUS	211215-001	Jul 25, 2019		RX	Yes	Yes	11,918,622
Maia Pharms Inc	LEVOTHYROXINE SODIUM	levothyroxine sodium	POWDER;INTRAVENOUS	208749-001	Dec 21, 2018	AP	RX	No	No

Paragraph IV (Patent) Challenges for MAIA PHARMS INC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	for Injection	200 mcg/vial		2015-05-01
	for Injection	100 mcg/vial and 500 mcg/vial		2015-04-14

International Patents for Maia Pharms Inc Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	3672616
World Intellectual Property Organization (WIPO)	2019040904
World Intellectual Property Organization (WIPO)	2023049346
Canada	3073944

Supplementary Protection Certificates for Maia Pharms Inc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2822954	LUC00083	Luxembourg		PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625
2203431	15C0013	France		PRODUCT NAME: DASABUVIR OU UN SEL DE CELUI-CI, NOTAMMENT LE SEL DE SODIUM; REGISTRATION NO/DATE: EU/1/14/983 20150119
2203431	CA 2015 00014	Denmark		PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
2673237	1990016-6	Sweden		PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; REG. NO/DATE: EU/1/17/1173 20180326
0290047	97C0108	Belgium		PRODUCT NAME: MANGAFODIPIR TRISODIUM (ANHYDROUS) CORRESP. MANGAFODIPIR; REGISTRATION NO/DATE: EU/1/97/040/001 19970522

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Maia Pharms Inc

Pharmaceutical Competitive Landscape Analysis: MAIA Biotechnology Inc – Market Position, Strengths & Strategic Insights

In the dynamic and highly competitive pharmaceutical industry, understanding the market landscape is crucial for success. MAIA Biotechnology Inc, a clinical-stage biopharmaceutical company, has emerged as a noteworthy player in the field of targeted immunotherapies for cancer. This comprehensive analysis delves into MAIA's market position, strengths, and strategic insights, providing valuable information for industry professionals and investors alike.

Company Overview

MAIA Biotechnology Inc (NYSE: MAIA) is a clinical-stage biopharmaceutical company focused on developing innovative targeted immunotherapies for cancer[1]. Founded with a mission to create first-in-class drugs with novel mechanisms of action, MAIA aims to significantly improve and extend the lives of cancer patients[4].

Core Technology and Lead Product

At the heart of MAIA's pipeline is THIO, a potential cancer telomere-targeting agent currently in clinical development[6]. THIO represents a unique approach in oncology, as it is believed to be the only direct telomere-targeting agent in clinical development[1].

THIO, a modified nucleoside, is currently in a Phase 2 trial for non-small cell lung cancer (NSCLC) in combination with Libtayo (cemiplimab, from Regeneron)[3].

This innovative approach positions MAIA at the forefront of telomere-targeting therapies, a promising area in cancer treatment.

Market Position and Competitive Landscape

Current Market Share

As of Q3 2024, MAIA Biotechnology's market share in terms of revenue was 0.00% within its competitive set[5]. This reflects the company's pre-revenue status, which is common for clinical-stage biopharmaceutical companies focused on research and development.

Competitive Set

MAIA's primary competitors in the biotechnology and pharmaceutical preparations industry include:

1. Bellicum Pharmaceuticals Inc
2. Fate Therapeutics Inc
3. Immunogen Inc
4. Iovance Biotherapeutics Inc
5. Verastem Inc[5]

While MAIA currently holds no market share in terms of revenue, it's important to note that the company's value lies in its potential future market position, contingent on the success of its clinical trials and eventual product commercialization.

SWOT Analysis

Strengths

1. Innovative Technology: MAIA's lead product, THIO, utilizes a unique, first-in-class mechanism targeting telomeres to selectively kill cancer cells[7].

2. Promising Clinical Data: Preliminary Phase 2 data in NSCLC has shown encouraging results, with disease control rates outpacing standard of care in both second- and third-line patients[7].

3. Multiple Indications: THIO holds orphan drug designations for hepatocellular carcinoma, small cell lung cancer, and glioblastoma, indicating potential across various cancer types[1].

4. Strategic Partnerships: MAIA has a clinical supply agreement with Regeneron for the use of Libtayo in combination with THIO in NSCLC trials[7].

Weaknesses

1. Pre-revenue Status: As a clinical-stage company, MAIA currently generates no revenue, relying on funding rounds and investments for operations[5].

2. Limited Product Pipeline: The company's focus on THIO as its primary asset could be a risk if clinical trials don't meet expectations.

3. Small Company Size: With only 13 employees reported, MAIA may face challenges in scaling operations compared to larger competitors[6].

Opportunities

1. Expanding Indications: Success in NSCLC could pave the way for THIO's application in other solid tumor types and earlier lines of therapy[7].

2. Potential Partnerships: MAIA's innovative technology could attract partnerships with larger pharmaceutical companies for development or commercialization.

3. Growing Oncology Market: The global oncology market is projected to continue growing, providing ample opportunities for novel therapies.

Threats

1. Competitive Landscape: The oncology field is highly competitive, with numerous companies developing novel therapies.

2. Regulatory Hurdles: The complex and stringent regulatory environment in pharmaceuticals could pose challenges for approval and commercialization.

3. Funding Risks: As a pre-revenue company, MAIA relies on external funding, which could be challenging in uncertain economic conditions.

Strategic Insights

Focus on Clinical Development

MAIA's primary focus in the near term should be on advancing THIO through clinical trials. The company plans to pursue accelerated approval in NSCLC in 2025, pending continued efficacy[7]. Successful trial outcomes could significantly boost the company's market position and attract investor interest.

Expansion of Indications

While NSCLC is the current focus, MAIA should continue exploring THIO's potential in other cancer types, particularly those for which it has received orphan drug designation. This strategy could help diversify the company's potential market and mitigate risks associated with a single-product focus.

Partnership Opportunities

Given the promising preliminary data for THIO, MAIA should actively seek partnerships with larger pharmaceutical companies. Such collaborations could provide additional resources for clinical development, manufacturing, and eventual commercialization.

Intellectual Property Strategy

MAIA should continue to strengthen its patent portfolio around THIO and its telomere-targeting technology. A robust IP strategy will be crucial for maintaining a competitive advantage in the rapidly evolving oncology landscape.

Financial Overview

As of the latest available data, MAIA Biotechnology's financial position reflects its status as a clinical-stage company:

• Market Capitalization: Approximately $20 million[7]
• Quick Ratio: 1.72
• Current Ratio: 1.77
• Return on Assets: -197.35%
• Return on Equity: -893.23%[6]

These figures underscore the company's pre-revenue status and the significant investments being made in research and development.

Future Outlook

MAIA Biotechnology's future prospects are closely tied to the success of THIO in clinical trials. The company's near-term milestones include:

1. Providing updated clinical data at upcoming conferences
2. Pursuing accelerated approval for THIO in NSCLC in 2025
3. Exploring potential partnerships for development in other cancer indications

If THIO continues to demonstrate strong efficacy and safety profiles, MAIA could potentially capture a significant share of the oncology market, particularly in areas with high unmet medical needs.

Key Takeaways

• MAIA Biotechnology is developing THIO, a novel telomere-targeting agent for cancer treatment.
• Preliminary Phase 2 data in NSCLC shows promising efficacy, outpacing standard of care.
• The company's market position is currently pre-revenue, with future value dependent on clinical trial success.
• MAIA faces both opportunities and challenges in the competitive oncology landscape.
• Strategic focus on clinical development, indication expansion, and partnerships will be crucial for future success.

FAQs

1. Q: What is MAIA Biotechnology's primary focus? A: MAIA Biotechnology focuses on developing targeted immunotherapies for cancer, with its lead product THIO targeting telomeres in cancer cells.

2. Q: How does THIO differ from other cancer treatments? A: THIO is believed to be the only direct telomere-targeting agent in clinical development, offering a unique approach to cancer treatment.

3. Q: What stage of development is THIO currently in? A: THIO is currently in Phase 2 clinical trials for non-small cell lung cancer (NSCLC).

4. Q: Does MAIA Biotechnology have any strategic partnerships? A: Yes, MAIA has a clinical supply agreement with Regeneron for the use of Libtayo in combination with THIO in NSCLC trials.

5. Q: What are the potential market opportunities for MAIA Biotechnology? A: If successful, THIO could potentially be used in multiple cancer types and earlier lines of therapy, representing a significant market opportunity in the growing oncology field.

Sources cited:

1. https://www.stocktitan.net/news/MAIA/
2. https://www.marketscreener.com/quote/stock/MAIA-BIOTECHNOLOGY-INC-141660673/news/MAIA-Biotechnology-NYSE-MAIA-Makes-Strategic-Moves-Key-Presentations-New-Funding-and-Leadershi-46782881/
3. https://dashboard.channelchek.com/wp-content/uploads/pdf/MAIA_20250108_27228.pdf
4. https://ir.maiabiotech.com/sec-filings/all-sec-filings/content/0001193125-24-284258/0001193125-24-284258.pdf
5. https://csimarket.com/stocks/competitionSEG2.php?code=MAIA
6. https://www.morningstar.com/stocks/xase/maia/quote
7. https://seekingalpha.com/article/4661122-maia-biotechnology-significantly-undervalued-novel-mechanism-impressive-early-data

Last updated: 2025-02-12